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Abstract 
Current treatment modalities for pancreatic carcinoma afford only modest survival benefits. 
TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new 
treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further 
improvements and optimizations are still needed. One strategy to improve the effectiveness of 
TRAIL-based therapies is to specifically target one of the two cell death inducing TRAIL-
receptors, TRAIL-R1 or TRAIL-R2 to overcome resistance. To this end, we designed constructs 
expressing soluble TRAIL (sTRAIL) variants that were rendered specific for either TRAIL-R1 or 
TRAIL-R2 by amino acid changes in the TRAIL ectodomain. When we expressed these 
constructs, including wild-type sTRAIL (sTRAILwt), TRAIL-R1 (sTRAILDR4) and TRAIL-R2 
(sTRAILDR5) specific variants, in 293 producer cells we found all to be readily expressed and 
secreted into the supernatant. These supernatants were subsequently transferred onto target 
cancer cells and apoptosis measured. We found that the TRAIL-R1 specific variant had higher 
apoptosis-inducing activity in human pancreatic carcinoma Colo357 cells as well as PancTu1 
cells that were additionally sensitized by targeting of XIAP. Finally, we tested TRAIL-R1 
specific recombinant TRAIL protein (rTRAILDR4) on Colo357 xenografts in nude mice and 
found them to be more efficacious than rTRAILwt.  Our results demonstrate the benefits of 
synthetic biological approaches and show that TRAIL-R1 specific variants can potentially 
enhance the therapeutic efficacy of TRAIL-based therapies in pancreatic cancer, suggesting that 
they can possibly become part of individualized and tumor specific combination treatments in the 
future. 
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Introduction 
The TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) was identified in the 1990s based 
on its sequence homology to other members of the TNF superfamily and is a type II 
transmembrane protein that can rapidly induce apoptosis. 1-4 It has been mostly used as a 
recombinant and soluble protein produced in bacteria and is made up of the TRAIL ectodomain 
that corresponds to amino acid 114 to 281 of the TRAIL amino acid sequence. It is usually 
referred to as recombinant TRAIL (rTRAIL) or simply TRAIL.5-7 An important and unique 
characteristic of TRAIL is its ability to selectively trigger receptor-mediated apoptosis in cancer 
cells but not in normal cells.8 For this reason, TRAIL has been extensively studied as an anti-
cancer reagent. TRAIL interacts with an intricate receptor system consisting of two apoptosis-
inducing agonistic death receptors, death receptor 4 (DR4/TRAIL-R1) and death receptor 5 
(DR5/TRAIL-R2), and three antagonistic or decoy receptors, decoy receptor 1 (DcR1/TRAIL-
R3), decoy receptor 2 (DcR2/ TRAIL-R4), and the soluble receptor osteoprotegerin (OPG). 9 
TRAIL binds as homotrimer to DR4 and DR5, which results in trimerization of the receptors and 
this leads to the recruitment of Fas-associated death domain (FADD), which in turn allows 
binding and activation of the initiator caspase, caspase-8. Mature caspase-8 molecules are 
capable to activate downstream effector caspases, which then execute apoptosis.10-12 DcR1 lacks 
a death domain and DcR2 contains a truncated death domain, so the binding of TRAIL to these 
receptors does not induce apoptosis but could instead prevent apoptosis by sequestering available 
TRAIL or by interfering with TRAIL-R1 or TRAIL-R2 signaling complexes.13-15 OPG is a 
secreted protein that functions as a decoy receptor for RANKL, 16 but may also act as decoy 
receptor for TRAIL and protect against apoptosis. 17 The resistance of normal, non-transformed 
cells to TRAIL-induced apoptosis is likely regulated at more levels than just presence of decoy 
receptors, but decoy receptors may be responsible for the unresponsiveness of some cancer cells. 
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18
 Consequently, one potential way of improving the therapeutic efficacy of TRAIL is to generate 
agents that act in a TRAIL-receptor specific way, preferring one of the two death receptors and 
potentially avoiding the decoy receptors. To this end, agonistic antibodies directed against one of 
the two apoptosis-inducing TRAIL-receptors have been developed and tested in various 
experimental systems as well as in the clinic. 19-22 In addition, engineered variants of TRAIL, 
containing specific amino acid changes leading to specific targeting of TRAIL-R1 or TRAIL-R2 
have been developed and have shown enhanced anti-tumor properties in-vitro and in-vivo. 23-31 
This is of particular interest in the case of pancreatic cancer as previous studies have shown that 
pancreatic tumor cells preferentially use TRAIL-R1 to execute TRAIL-induced apoptosis. 32, 33 
While these studies were carried out with agonistic antibodies against TRAIL-R1, TRAIL 
variants that possess specificity for TRAIL-R1 might hold important advantages such as the fact 
that they are smaller than antibodies and might therefore better able to reach and infiltrate 
growing tumors. Moreover, such proteins can be further engineered and optimized to increase 
activity, specificity and stability, and are potentially easier to produce and to test. Therefore, we 
generated TRAIL-receptor specific TRAIL variants based on earlier published amino acid 
sequence changes 24, 26, 28-30 and tested them on pancreatic cancer cells in-vitro and in-vivo. We 
utilized recombinant TRAIL (rTRAIL) variant proteins as well as a gene expression system that 
we described previously and gives rise to secreted and soluble TRAIL (sTRAIL). 27, 34, 35 This 
system, in principle, also allows for high-throughput analyses of TRAIL variants as new mutants 
would not have to be expressed in bacteria and the protein purified before they can be tested on 
tumor cells and can also be integrated into various gene and cellular delivery vehicles. Here, we 
show that both rTRAIL and sTRAIL variants directed against TRAIL-R1 possess higher 
apoptosis inducing activity in pancreatic cancer cells as compared to TRAIL-R2 specific variants 
and wild-type rTRAIL and sTRAIL. Thus, our study highlights that TRAIL-R1 specific variants 
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constitute a potential improvement to conventional TRAIL therapies and might be able to 
overcome apoptosis resistance particularly in pancreatic cancers. 
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Results 
TRAIL-receptor specific sTRAIL variants are expressed and secreted 
DNA fragments encoding the signal peptide of the human fibrillin-1 gene (hFIB) gene, the Furin 
cleavage site (Furin CS), an Isoleucine zipper (ILZ) and the ectodomain of TRAIL (aa114-aa281; 
sTRAIL) were ligated together (Fig. S1). The hFIB signaling peptide leads to effective secretion 
of sTRAIL while the Furin CS mediates the removal of the signal peptide, while the ILZ forces 
the formation of trimeric sTRAIL, which has higher activity than monomeric sTRAIL. In 
addition to the common wild-type TRAIL construct (sTRAILwt) containing the consensus TRAIL 
cDNA sequence, we engineered one TRAIL-R1 (DR4) specific sTRAIL variant, termed 
sTRAILDR4 and one specific for TRAIL-R2 (DR5), labeled sTRAILDR5 (Fig. S2). Both 
sTRAILDR4 and sTRAILDR5 contained only one amino acid exchange, namely S159R and D269H, 
respectively (Fig. 1A). 27 These two expression cassettes together with sTRAILwt were cloned 
into pCDNA3.1 and along an EGFP control plasmid were transfected into 293 cells. Subsequent 
Western blot analyses demonstrated that the two sTRAIL variants were expressed (Fig. 1B) and 
ELISA measurements of the 293 cell supernatants revealed that sTRAIL variants were indeed 
secreted (Fig. 1C). The results demonstrated that the different sTRAIL variants were expressed 
and secreted to approximately the same levels as sTRAILwt and that our expression system can be 
used as an alternative to recombinant proteins as part of gene and cellular therapeutic approaches. 
In addition, the system serves as an easy test system for novel TRAIL variants or other 
therapeutic proteins without the need for laborious and time-consuming recombinant protein 
production and purification.  
 
Apoptosis induction by sTRAILDR4 in pancreatic cancer cells 
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Using TRAIL-receptor specific antibodies we and others have recently shown that TRAIL-
induced apoptosis is preferentially mediated via TRAIL-R1 in pancreatic carcinoma cells. 32, 33 
Therefore, we set out to test our sTRAILDR4 variant in pancreatic tumor cells and to compare it to 
sTRAILDR5 and sTRAILwt. For this, we transfected 293 cells with the four constructs expressing 
EGFP (ctrl), sTRAILwt, sTRAILDR5 and sTRAILDR4, respectively, harvested the supernatant 
media after 48 h, measured the sTRAIL concentration by ELISA and applied 8 ng/ml, 2 ng/ml, 
0.5 ng/ml and 0.25 ng/ml onto Colo357 pancreatic cancer cells. After 24 h exposure to the 
sTRAIL variants we measured apoptosis. We found that at 8 ng/ml the three sTRAIL types 
(sTRAILwt, sTRAILDR5 and sTRAILDR4) had very similar apoptosis-inducing activities (Fig. 2A). 
Even though there was a trend towards increased cell death with sTRAILDR4, the difference was 
not significant. Added onto Colo357 cells at 2 ng/ml, sTRAILDR4 triggered relatively more 
apoptosis than sTRAILDR5, but still provided no significant advantage over sTRAILwt (Fig 2B). 
However, at lower concentrations of sTRAILDR4 (0.5 ng/ml and 0.25 ng/ml) it showed 
significantly higher levels of apoptosis as compared to sTRAILwt and sTRAILDR5 (Fig. 2C and 
2D). 
Moreover, in HeLa cervical cancer cells and HL-60 acute myeloid leukemia (AML) cells, we 
also found a preference to undergo apoptosis via TRAIL-R1, confirming results with purified 
recombinant TRAIL variant  protein (Fig. 2E and 2F). 36, 30 
 
Effects of rTRAILDR4 on pancreatic cancer cells in-vitro 
Next, we tested recombinant rTRAILDR4 and rTRAILwt protein on Colo357 cells. These proteins 
were generated and purified as described previously. 37 We applied the two proteins at a 
concentration of 100 ng/ml for 24 h before we measured apoptosis. The results reveal that 
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rTRAILDR4 led to significantly more apoptosis than rTRAILwt in Colo357 cells corroborating our 
result with the sTRAIL variants (Fig. 3A).  
As not all pancreatic cancer cells are principally TRAIL sensitive and we and others have 
recently reported that TRAIL-induced apoptosis is preferentially mediated via TRAIL-R1 in 
pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors 32, 33, we tested the 
utility of TRAIL-R1 specific variants in conjunction with XIAP inhibition. When we treated 
XIAP-silenced PancTu1 (PancTu1.shXIAP) cells with rTRAILwt and rTRAILDR4, we could 
measure apoptosis in all cases, but rTRAILDR4 gave rise to significantly higher cell death rates 
than rTRAILwt (Fig. 3B). These findings are in line with our previous findings 32, 33 and underline 
that pancreatic cancer cells undergo apoptosis preferentially via TRAIL-R1 even in cases where 
the TRAIL treatment has to be combined with targeting of other molecules such as XIAP.  In 
summary, TRAIL receptor specific variants offer a substantial improvement over normal TRAIL 
as they can better target TRAIL resistant cancer cells and act more specifically and effectively in 
combined treatment approaches.  
 
The effect of rTRAILDR4 in pancreatic cancer cell-derived xenografts 
After having demonstrated the effectiveness and specificity of our TRAILDR4 specific variant we 
tested and compared rTRAILDR4 and rTRAILwt in Colo357 xenografts. First, we established 
tumors in immune-deficient nu/nu mice by subcutaneously injecting 5x105 Colo357 cells into the 
flank. After ten days when the tumors where palpable, the animals were injected intraperiteonally 
with 5 mg/kg rTRAILwt and rTRAILDR4 proteins, respectively. The injections were repeated daily 
over a period of 10 days. During this time and 13 additional days following the conclusion of the 
treatment schedule the sizes of the tumors were followed. The results of this study show that both 
rTRAILwt and rTRAILDR4 had a significant tumor regressive effect compared to the carrier (PBS 
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buffer). In addition, this effect was slightly larger in the rTRAILDR4 mice than in rTRAILwt 
treated animals (Fig. 4A). Histological analyses of these tumors confirmed the better anti-
neoplastic activity of rTRAILDR4 over rTRAILwt on Colo357 xenografts (Fig 4B), as we detected 
increased connective tissue formation in tumors treated with rTRAILDR4 by trichrome staining. 
These results are indicative of higher levels of apoptosis in cancer cells in the rTRAILDR4 treated 
xenografts, since dead tumor cells are being replaced by scar tissue. Moreover, tissue sections 
from liver, bone marrow and spleen from rTRAILwt and rTRAILDR4 injected animals showed no 
abnormalities demonstrating a lack of toxic side effects from these treatments (Fig. 4C). Taken 
together, TRAIL-R1 specific variants have enhanced apoptosis-inducing effects in pancreatic 
cancer cells in-vitro and show a trend towards greater therapeutic efficacy in-vivo and warrant 
further investigation with the goal to optimize TRAIL-based therapies in the future.  
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Discussion 
While TRAIL is generally a potent inducer of apoptosis in various tumor cells, several other 
cancer cells are resistant owing to a variety of molecular mechanisms. The resistance to TRAIL 
can occur at multiple steps in the TRAIL signaling pathway. 38 Various studies 39, 40 found an NF-
B mediated survival mechanism involving NF-B target genes such as XIAP, c-Flip and/or Bcl-
xL. 
41
 In fact, in many cancer cells XIAP was found to be over-expressed in comparison to normal 
cells and several studies have confirmed the involvement of this anti-apoptotic protein in TRAIL 
resistance as inhibition of XIAP either chemically or by RNAi yielded an increase in cell death 
after TRAIL treatment in different types of cancer. 42-45 Similarly, Bcl-xL 46 and c-Flip 47-49 have 
been shown to confer TRAIL-resistance to tumor cells. However, we found that in pancreatic 
cancer cells XIAP had a dominant role and that Bcl-xL and c-Flip had either a modest or no 
function in apoptosis resistance. 35, 50 Noteworthy, silencing of XIAP by RNAi resulted in 
substantial and significant TRAIL sensitization, but only additional pro-apoptotic signals such as 
adenoviral-mediated overexpression of TRAIL-R1 or IFN--induced increases in caspase-8 levels 
resulted in very high cell death rates of 70-90%, 50 clearly indicating that both excessive anti-
apoptotic factors and limiting pro-apoptotic functions contribute to apoptosis resistance. Thus, in 
the present study we turned to variants of TRAIL that are specific for TRAIL-R1 or TRAIL-R2 
to augment the pro-apoptotic responses in cancer cells by circumventing the inhibitory functions 
of the two decoy receptors, TRAIL-R3 and TRAIL-R4. In addition, the functional unit of 
TRAIL-receptors is a trimer, and in this context it is thought that in principle TRAIL-R1 or 
TRAIL-R2 homotrimers possess higher apoptosis-inducing activities than heterodimers 
containing both TRAIL-R1 and TRAIL-R2 or even decoy receptor molecules. 27, 51-53 Therefore, 
TRAIL-receptor specific variants could possess more pro-apoptotic activity, as they would tend 
to assemble homotrimers. However, as cancer cells often prefer to trigger apoptosis either via 
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TRAIL-R1 or TRAIL-R2 27, it is important to determine the preference and then use TRAIL 
variants in an individualized manner. Pancreatic cancers have been reported to mainly utilize 
TRAIL-R1. 32, 33 Therefore, we tested a TRAIL-R1 specific variant on two different pancreatic 
cancer cell lines along with a TRAIL-R2 specific variant and wild-type TRAIL. We found that 
the TRAIL-R1 variant had superior apoptosis-inducing activities when compared to the other 
forms of TRAIL. In these studies we used expression constructs that contained the sequence for 
the ectodomain of TRAIL including specific single point mutations that serve to change the 
specificity towards one of the two TRAIL death receptors. These TRAIL ectodomain encoding 
cDNA segments were ligated to an ILZ stretch that enforces the trimerization of TRAIL 
molecules turning it into a more active protein. The secretion of this fusion protein consisting of 
sTRAIL and the ILZ domain is facilitated by an exogenous signal peptide and a cleavage site for 
the ubiquitous protease Furin. 34 Such expression cassettes can be integrated into viral vector 
systems for cancer gene therapeutic approaches 54 or they can be used in connection with cellular 
delivery vehicles such as mesenchymal stem cells (MSCs) that can infiltrate tumor tissues where 
they produce and secrete sTRAIL, which in turn acts on the neighboring cancer cells. 35, 55, 56 In 
the present study we initially transfected our TRAIL constructs into 293 cells that produced and 
secreted the different sTRAIL variants. After harvesting of the sTRAIL containing supernatants, 
measuring and normalizing of TRAIL concentrations, the supernatants were transferred onto 
cancer cells and apoptosis measured. We could show that these expressed and secreted variants 
behaved similarly to the equivalent recombinant proteins and can therefore be used inside of gene 
and cell therapeutic vectors providing the same specificity for TRAIL-R1 and TRAIL-R2, 
respectively.  
In addition, this system allows for faster and more effective testing of potential further sTRAIL 
variants sparing the expensive and time-consuming need for purification of recombinant proteins 
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from bacterial lysates. Numerous new TRAIL variants could be generated by PCR-based random 
mutagenesis, 57 cloned into our expression plasmid backbone and directly tested for their activity 
and specificity on cancer cells after transfection into 293 cells. Thus, our system could greatly 
enhance the search for optimized TRAIL variants and possibly other therapeutic proteins. 
Having demonstrated the general utility of our TRAIL variants and in particular the superior 
apoptosis-inducing activity of the TRAIL-R1 variant on Colo357 pancreatic cancer cells, we 
turned to an in-vivo model. To this end, we examined the effects of recombinant wild-type and 
TRAIL-R1 specific TRAIL protein in Colo357 xenografts. The results showed that the 
rTRAILDR4 protein displayed significantly better anti-tumor efficacy when compared to the 
control cohort (PBS). Even though, the difference between rTRAILDR4 and rTRAILwt failed to 
reach significance in this study, we observed an increase in scar tissue formation in tumors 
treated with rTRAILDR4 as compared to wild-type TRAIL, which shows that more tumor tissue is 
replaced by connective tissue indicative of higher cancer cell killing. Taken together, these results 
suggest a higher effectivity of rTRAILDR4 and further highlight the potential utility of TRAIL-R1 
specific variants in pancreatic cancer. 
However, the overall efficacy of the rTRAILDR4 protein still leaves room for improvements such 
as integration of an ILZ domain or additional changes to the protein sequence to make the protein 
more stable and/or more active in-vivo. Our expression system as discussed above is well suited 
to identify such novel variants. Moreover, cellular delivery vehicles such as MSCs could be used 
to enhance availability of TRAIL in tumor tissues and TRAIL could be combined with 
conventional chemotherapeutic drugs for increased anti-tumor effects. 3, 35, 55, 58 
In summary, our results demonstrate that TRAIL-receptor specific TRAIL variants are a 
significant improvement and represent a significant step forward to increase the potential for 
clinical tests and use of MSC-based delivery of TRAIL as part of a tumor-specific and patient-
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tailored therapy. In particular aggressive pancreatic cancer that is difficult to treat successfully is 
a possible target for such novel treatment approaches. 
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Materials and Methods 
Reagents and cell culture: All chemicals, unless otherwise stated, were purchased from Sigma 
(St. Louis). Antibodies used in this study were sheep anti-CuZnSOD (The Binding Site) and 
rabbit anti-TRAIL (Peprotech) mouse anti-XIAP (BD Bioscience). Peroxidase-conjugated 
secondary antibodies were anti-mouse, anti-rabbit and anti-sheep (Santa Cruz). 
Human cervix carcinoma HeLa cells (ATCC), human pancreatic cancer PancTu1 cells (gift from 
Simone Fulda) as well as human embryonic kidney 293 cells (Life Technologies) were grown in 
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% FBS, 100 U/ml penicillin 
and 100 g/ml streptomycin. HL-60 and Colo357 (gifts from Eva Szegezdi) were grown in 
RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml 
streptomycin.  
Generation of TRAIL constructs: Generation of sTRAIL constructs and site-directed 
mutagenesis have been previously described. 27 Further information and details can be found in 
the Supplementary Material and Methods section.  
Apoptosis assay Apoptosis was measured according to Nicoletti et al. 59 and has been described 
previously 60.  
Transfection of 293 cells: For the transfection of 293 cells (5x105 cells/well) we used the 
calcium phosphate transfection method which has been previously described. 27 Supernatants of 
transfected 293 cells were cleared by centrifugation and diluted to determine the TRAIL 
concentration by ELISA.  
Animal studies: Ten week old female CD1 nu/nu mice (Charles River, Wilmington, MA) were 
injected with 5x106 Colo357 cells in 200 µl PBS. After ten days and when tumors were palpable 
the animals were intraperitoneally daily injected with purified rTRAIL (wt and DR4) at a 
concentration of 5 mg/kg over a period of 10 days. The growth of the tumors was followed over 
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23 days. The tumor volume was calculated using three different diameters and the formula: 
π/6*(d1*d2*d3). The animal studies were performed according to national laws and covered by 
license. 
Histological analyses: Tumor, liver, bone marrow and spleen samples taken during necropsy 
were fixed in 10% neutral-buffered formalin, paraffin embedded and 4-μm sections were stained 
with hematoxylin and eosin (H&E). Bone marrow samples were decalcified before processing. 
Additionally Masson’s Trichrome staining was carried out on tumor sections as follows.  Slides 
were rinsed and placed in Bouin’s solution overnight at room temperature. The next day, slides 
were washed, stained with Weigert Hematoxylin for 10 min, rinsed in distilled water and stained 
with Biebrich scarlet-acid fuchsin for 5 min followed with immersion in 
phosphomolybdic/phosphotungstic acid solution for 15 min and stained with aniline blue for 5 
min.  Slides were then rinsed, dehydrated with 95% and absolute alcohol and mounted. 
Western Blot: Western blots were carried out as described previously.61 Briefly, cells were 
harvested and lyzed in cell lysis buffer. Proteins were separated by SDS-PAGE and transferred 
onto PVDF membranes (GE Healthcare Biosciences). Primary and secondary antibodies were 
diluted in TBS, 0.1% Tween and 3% BSA. Bands were visualized with ECL Western blotting 
Substrate (Pierce). 
TRAIL Enzyme-linked Immunosorbent Assay (ELISA): To examine secreted sTRAIL, the 
culture supernatants of transfected 293 cells were cleared by centrifugation at 2,000 g for 20 min. 
The supernatants were diluted 20-fold and a commercial TRAIL ELISA kit (R&D Systems) was 
used following the manufacturer’s instructions.  
RNAi knock-down constructs and stable cell line generation: The following small hairpin (sh) 
RNA motif was used to target: XIAP (5´-GTGGTAGTCCTGTTTCAGC-3’) and has been 
previously described.39 Sense and antisense oligos containing the sh-sequence and 5’ overhang 
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representing a restricted BbsI site and EcoRI site on the 3’ side were hybridized to generate 
double-stranded DNA fragments. These fragments were then cloned into a modified pU6.ENTR 
plasmid (Life technologies). The resulting pU6.ENTR plasmid was used to generate the 
pBlockIt.shXIAP plasmid using the pBlockIt vector (Life Technologies) and LR Clonase II. This 
was used to generate stable XIAP knockdown clones of PancTu1 cells. For this, pBlockit.shXIAP 
plasmids were FuGene-transfected (Roche) into PancTu1 cells. Three days later, the transfected 
cells were split into Blasticidin containing selection medium. Arising clones were picked, 
transferred to 24 well-plates and tested for XIAP silencing, respectively. Clones that did not show 
a knock-down were used as controls labeled PancTu1.shctrl. These control clones were tested and 
shown to behave like parental PancTu1 cells. 
Statistical Analysis: If not stated, three independent experiments were performed. Experimental 
values are expressed as mean value ± standard error (SEM). For significance analyses, analysis of 
variance (ANOVA) between groups was used and P<0.05 was considered significant and P<0.01 
as highly significant.  
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Figure Legends 
Figure 1.  Generation and expression of sTRAIL specific variants. (A): Table showing the 
mutations in sTRAILwt leading to sTRAILDR5 (TRAIL-R2 specific) and sTRAILDR4 (TRAIL-R1 
specific) variants. The TRAIL receptor specific variants were generated by site-directed 
mutagenesis inserting a D269H amino acid change (sTRAILDR5) and an amino acid change 
(S159R) to generate sTRAILDR4 in the sTRAIL ectodomain. (B): All three sTRAIL expression 
constructs were transiently transfected into 293 cells. After 24 h whole cell lysates were analyzed 
by Western blotting for TRAIL revealing similar expression levels for all three constructs. As 
control, expression from a conventional construct encoding membrane-bound, full-length TRAIL 
(FL) without hFIB, Furin CS or ILZ segments was also analyzed. EGFP transfected cells (ctrl) 
served as additional control. CuZnSOD was used as a loading control (C):  Results of ELISA 
analyses for TRAIL showing the levels of secreted sTRAILwt (brown), sTRAILDR5 (red) and 
sTRAILDR4 (green) into the supernatant of transfected 293 cells. Results for cells transfected with 
the EGFP control plasmid (ctrl; grey) are also shown.  
 
Figure 2. Colo357 pancreatic cancer cells die preferentially through TRAIL-R1  (A-D): 
Supernatants from 293 cells that were transfected with EGFP (ctrl; grey), sTRAILwt (brown), 
sTRAILDR5 (red), and sTRAILDR4 (green) constructs were then transferred onto Colo357 
pancreatic cancer cells at 8 ng/ml (A), 2 ng/ml (B), 0.5 ng/ml (C) and 0.25 ng/ml (D). After 24 h 
apoptosis was measured. (E):  HeLa cells were incubated with the same EGFP (grey), sTRAILwt 
(brown), sTRAILDR5 (red), and sTRAILDR4 (green) 293 cell supernatants at 2 ng/ml of TRAIL for 
24 h before apoptosis was measured. (F): HL-60 cells were also incubated with EGFP (grey), 
sTRAILwt (brown), sTRAILDR5 (red), and sTRAILDR4 (green) 293 cell supernatants (8 ng/ml of 
sTRAIL). 24 h later apoptosis was measured.  
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Figure 3. Apoptosis analyses of pancreatic carcinoma cells treated with rTRAILwt and 
rTRAILDR4. (A): Colo357 cells were treated with PBS (grey) as control, 100 ng/ml rTRAILwt 
(rwt; brown) and rTRAILDR4 (rDR4; green) for 24 h before apoptosis was measured. The 
apoptosis was significantly higher with rTRAILDR4 than rTRAILwt. (B): PancTu1.shctrl (filled) 
and PancTu1.shXIAP (dashed) cells were treated with PBS (grey) as control, 100 ng/ml 
rTRAILwt (rwt; brown) and rTRAILDR4 (rDR4; green) for 24 h before apoptosis was measured. 
The results show that PancTu1.shctrl cells are TRAIL resistant and that silencing of XIAP (in 
PancTu1.shXIAP) sensitizes the cells. In PancTu1.shXIAP rTRAILDR4 induces significantly 
more apoptosis than rTRAILwt. In the insert the knock-down of XIAP is shown by Western blot 
of protein lysates from PancTu1.shXIAP (lane 1) and PancTu1.shctrl (lane 2) cells. The 
CuZnSOD blot serves as loading control. 
 
Figure 4. Treatment with rTRAIL variants lead to remission of Colo357 xenografts. (A): 
Immune-deficient mice were injected with 5x106 Colo357 cells. After 10 days (= day 0 of 
treatment regimen) 5 mg/kg rTRAILDR4 (green line; n=3) were injected intraperitoneally. 
Treatments were repeated daily over 10 days. Animals in two additional groups received the 
same schedule with rTRAILwt (red line; n=3) and PBS (grey line; n=3), respectively. The tumor 
growth was followed over 23 days in total and the values are depicted in the graph. (B): 
Trichrome staining of tumor sections from mice treated with PBS, rTRAILwt and rTRAILDR4 (C): 
H&E staining of liver, bone marrow and spleen sections from mice treated with PBS, rTRAILwt 
and rTRAILDR4, respectively.  
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The sTRAIL constructs 
The soluble portion of human TRAIL (amino acids 114-281; sTRAIL) was first subcloned 
into the NheI/NotI sites of an EcoR1-cut and re-circularized pDRIVE vector (Qiagen). First, 
the sTRAIL fragment was amplified by PCR from a pcDNA3 plasmid containing the full-
length cDNA of TRAIL (aa1-aa281). The following primers with Nhe1 and Not1 overhangs 
were used: Forward 5’-GCTAGCGTGAGAGAAAGAGGTCCTCAGAGAG-3’; Reverse 5’-
GCGGCCGCTTAGCCAACTAAAAAGGCCCCGA-3’. The PCR fragment was cloned into 
a normal pDRIVE (Qiagene) vector, released with Nhe1 and Not1 and then ligated into the 
re-circularized pDRIVE plasmid that was opened up with Nhe1 and Not1. The plasmid was 
called pDRIVE.TRAIL-114. Subsequently, the fragments for the signal peptide from the 
human fibrillin 1 gene (aa1-aa27), a Furin cleavage site (aa28-aa37) and the isoleucine zipper 
(aa38-aa74) were cloned into pDRIVE.TRAIL-114 with BamH1/EcoR1, EcorR1/Sal1 and 
Sal1/Nhe1, respectively. These fragments were generated by hybridizing corresponding sense 
and antisense oligonucleotides with the respective restriction endonuclease overhangs listed 
above. The amino acid sequence of the resulting sTRAIL transgene product is depicted in 
Fig. S1. 
TRAIL variants, sTRAILDR5 (D269H) and sTRAILDR4 (S159R) were generated using the 
Quick-Change site-directed mutagenesis kit (Stratagene, La Jolla, CA) and confirmed by 
DNA sequencing Fig. S2. 
 
 
MRRGRLLEIALGFTVLLASYTSHGADAEFSARNRQKRVDRMKQIEDKIEEILSKIYHIENEI
ARIKKLIGERASVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSF
LSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKS
ARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG* 
 
Fig. S1: The sTRAIL construct contains the signal peptide from the human Fibrillin 1 gene 
(pink), a cleavage site recognized by the ubiquitous protease Furin (blue), an Isoleucine 
zipper domain (green) and the ectodomain of TRAIL (red).  
  
sTRAILDR5 (D269H)  
MRRGRLLEIALGFTVLLASYTSHGADAEFSARNRQKRVDRMKQIEDKIEEILSKIYHIENEI
ARIKKLIGERASVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSF
LSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKS
ARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMHHEASFFGAFLVG* 
 
sTRAILDR4 (S159R) 
MRRGRLLEIALGFTVLLASYTSHGADAEFSARNRQKRVDRMKQIEDKIEEILSKIYHIENEI
ARIKKLIGERASVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRRGHSF
LSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKS
ARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG* 
 
Fig. S2: The sTRAILDR5 and sTRAILDR4 constructs also contain the signal peptide from the 
human Fibrillin 1 gene (pink), a cleavage site recognized by the ubiquitous protease Furin 
(blue), an Isoleucine zipper domain (green) and the ectodomain of TRAIL (red). The specific 
mutations in the s TRAIL part are highlighted in yellow.  
 
